Literature DB >> 29086227

A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.

Masahide Hiyoshi1, Atsushi Nanashima2, Takashi Wada2, Yuki Tsuchimochi2, Takeomi Hamada2, Koichi Yano2, Naoya Imamura2, Yoshiro Fujii2.   

Abstract

Pancreatic cancer patients have a poor prognosis because of a low rate of resection that results from distant metastases or local advancement. We report a successful case of unresectable locally advanced pancreatic cancer in a patient who was curatively resected after combination therapy with nab-paclitaxel (nab-PTX) and gemcitabine (GEM). A 61-year-old man was referred for treatment of a 45-mm pancreatic tail tumor involving the celiac axis, common hepatic artery, and splenic artery that appeared as an abnormal soft-density mass on imaging. This patient's tumor was defined as unresectable due to local advancement, and, therefore, the powerful combined chemotherapy regimen of nab-PTX with GEM was initiated to allow for possible resection later. After three cycles of chemotherapy, a CT scan revealed that the soft-density mass around the celiac axis and common hepatic artery had dramatically disappeared, and the tumor was then determined to be a resectable lesion. Thus, distal pancreatectomy with en bloc celiac axis resection was performed and curability was achieved. There has been no tumor recurrence or distant metastasis at more than 12 months after surgery, and the patient remains alive at 17 months after initial chemotherapy.

Entities:  

Keywords:  Conversion surgery; Curative resection; Gemcitabine; Locally advanced pancreatic cancer; Nab-paclitaxel

Mesh:

Substances:

Year:  2017        PMID: 29086227     DOI: 10.1007/s12328-017-0793-5

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  29 in total

Review 1.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.

Authors:  Claudio Bassi; Giovanni Marchegiani; Christos Dervenis; Micheal Sarr; Mohammad Abu Hilal; Mustapha Adham; Peter Allen; Roland Andersson; Horacio J Asbun; Marc G Besselink; Kevin Conlon; Marco Del Chiaro; Massimo Falconi; Laureano Fernandez-Cruz; Carlos Fernandez-Del Castillo; Abe Fingerhut; Helmut Friess; Dirk J Gouma; Thilo Hackert; Jakob Izbicki; Keith D Lillemoe; John P Neoptolemos; Attila Olah; Richard Schulick; Shailesh V Shrikhande; Tadahiro Takada; Kyoichi Takaori; William Traverso; Charles R Vollmer; Christopher L Wolfgang; Charles J Yeo; Roberto Salvia; Marcus Buchler
Journal:  Surgery       Date:  2016-12-28       Impact factor: 3.982

2.  Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.

Authors:  Tetsuhito Muranaka; Masaki Kuwatani; Yoshito Komatsu; Kentaro Sawada; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Satoshi Yuki; Yoshimasa Kubota; Kimitoshi Kubo; Shuhei Kawahata; Kazumichi Kawakubo; Hiroshi Kawakami; Naoya Sakamoto
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer.

Authors:  S Kondo; H Katoh; T Shimizu; M Omi; S Hirano; Y Ambo; S Okushiba; T Morikawa
Journal:  Hepatogastroenterology       Date:  2000 Sep-Oct

Review 4.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

5.  Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.

Authors:  Ken-Ichi Okada; Seiko Hirono; Manabu Kawai; Motoki Miyazawa; Atsushi Shimizu; Yuji Kitahata; Masaki Ueno; Shinya Hayami; Hiroki Yamaue
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

6.  Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.

Authors:  Hidenori Takahashi; Hiroaki Ohigashi; Osamu Ishikawa; Hidetoshi Eguchi; Kunihito Gotoh; Terumasa Yamada; Akihiko Nakaizumi; Hiroyuki Uehara; Yasuhiko Tomita; Kinji Nishiyama; Masahiko Yano
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

7.  Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Authors:  Fuyuhiko Motoi; Michiaki Unno; Hidenori Takahashi; Takaho Okada; Keita Wada; Masayuki Sho; Hiroaki Nagano; Ippei Matsumoto; Sohei Satoi; Yoshiaki Murakami; Masashi Kishiwada; Goro Honda; Hisafumi Kinoshita; Hideo Baba; Shoichi Hishinuma; Minoru Kitago; Hidehiro Tajima; Hiroyuki Shinchi; Hiroshi Takamori; Tomoo Kosuge; Hiroki Yamaue; Tadahiro Takada
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-08-01       Impact factor: 7.027

8.  Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.

Authors:  Hideki Ueno; Masafumi Ikeda; Makoto Ueno; Nobumasa Mizuno; Tatsuya Ioka; Yasushi Omuro; Takako Eguchi Nakajima; Junji Furuse
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-03       Impact factor: 3.333

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Authors:  R Alvarez; M Musteanu; E Garcia-Garcia; P P Lopez-Casas; D Megias; C Guerra; M Muñoz; Y Quijano; A Cubillo; J Rodriguez-Pascual; C Plaza; E de Vicente; S Prados; S Tabernero; M Barbacid; F Lopez-Rios; M Hidalgo
Journal:  Br J Cancer       Date:  2013-08-01       Impact factor: 7.640

View more
  3 in total

1.  Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.

Authors:  Ryosuke Okura; Shigetsugu Takano; Tetsuo Yokota; Hideyuki Yoshitomi; Shingo Kagawa; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Daisuke Suzuki; Nozomu Sakai; Hiroyuki Nojima; Takashi Mishima; Masaru Miyazaki; Masayuki Ohtsuka
Journal:  Mol Clin Oncol       Date:  2018-08-01

2.  Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma: A case report.

Authors:  Masahide Hiyoshi; Kengo Kai; Takeomi Hamada; Koichi Yano; Naoya Imamura; Atsushi Nanashima
Journal:  Int J Surg Case Rep       Date:  2022-04-18

3.  The Potential Therapeutic Role of Exosomal MicroRNA-520b Derived from Normal Fibroblasts in Pancreatic Cancer.

Authors:  Huijuan Shi; Hui Li; Tiantian Zhen; Yu Dong; Xiaojuan Pei; Xiangliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-10       Impact factor: 10.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.